SPRAVATO®

for Treatment-Resistant Depression (TRD)

• Proven efficacy with safety evaluated in over 1700 adults with treatment-resistant depression (TRD) across six studies: Five Phase 3 studies and one Phase 2 dose ranging study1

A distinct treatment approach

FDA-approved for over 4 years

Nasal spray formulation

Use and Restrictions:

SPRAVATO® (esketamine) CIII Nasal Spray is prescribed alongside an oral antidepressant to address:

- Treatment-resistant depression (TRD) in adults.

- Depressive symptoms in adults with major depressive disorder (MDD) exhibiting acute suicidal ideation or behavior.

Restrictions:

The efficacy of SPRAVATO® in preventing suicide or diminishing suicidal thoughts/behavior has not been proven. The use of SPRAVATO® does not eliminate the need for hospitalization if deemed clinically necessary, even if there is improvement following initial SPRAVATO® administration.

SPRAVATO® is not approved as an anesthetic. The safety and efficacy of SPRAVATO® as an anesthetic have not been established.

SPRAVATO® combined with an oral antidepressant demonstrated rapid and superior enhancement in depressive symptoms versus placebo + oral AD and provides your patients with a consistent safety profile and minimal risk of sexual dysfunction.

• A different treatment approach
• FDA-approved for over 4 years
• Nasal spray formulation

Indications and Limitations of Use:

SPRAVATO® (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant, for the treatment of:

• Treatment-resistant depression (TRD) in adults.
• Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Limitations of Use:

• The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®.
• SPRAVATO® is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO® as an anesthetic agent have not been established.

SPRAVATO® + oral AD demonstrated rapid and superior improvement in depressive symptoms compared to placebo + oral AD and offers your patients a consistent safety profile with minimal risk for sexual dysfunction